000			03218cam a2200349 a 4500
003			EG-GiCUC
005			20250223032528.0
008			200224s2020 ua dho f m 000 0 eng d
040			_aEG-GiCUC _beng _cEG-GiCUC
041	0		_aeng
049			_aDeposite
097			_aPh.D
099			_aCai01.19.05.Ph.D.2020.Hi.E
100	0		_aHisham Hany Ahmed Moneib
245	1	0	_aErythropoietin therapy after allogeneic hematopoietic cell transplantation in paediatric cancer patients / _cHisham Hany Ahmed Moneib ; Supervised Alaa Mohamed Elhaddad , Lobna Mohamed Shalaby , Mohamed Khaled Elmenabbawy
246	1	5	_aالعلاج بالارثروبويتين بعد زراعة الخلايا الجذعية من متبرع فى مرضى سرطان الاطفال
260			_aCairo : _bHisham Hany Ahmed Moneib , _c2020
300			_a89 P. : _bcharts , facimiles ; _c25cm
502			_aThesis (Ph.D.) - Cairo University - National Cancer Institute - Department of Pediatric Oncology
520			_aIntroduction Allogeneic hematopoietic cell transplantation (AHSCT) is potentially curative treatment for many patients with hematological malignancy. As a result of the myeloablative conditioning, almost all patients experience prolonged anemia and will require red blood cell transfusions. In this study, we report the results of the use of Recombinant human erythropoietin (rHuEPO) therapy for treatment of anemia in different hematological malignancies, evaluating the efficacy and safety of administration in pediatric patients undergoing AHSCT. Patients and Methods This was a prospective double arm randomized controlled study of consecutive pediatric cancer patients who underwent allogeneic HSCT at the Children{u2019}s Cancer Hospital Egypt (CCHE 57357) between 2015 and 2017 with a minimum follow up duration of one year post transplant. All eligible patients received myeloablative conditioning. All patients had matched related donors. Erythropoietin therapy was initiated at Day + 14 and continued till Day +100 with a dose of 150 U/kg 3 times per week, till hemoglobin of 12 g/dL then the dose was modified to 150 U/kg twice weekly. The primary outcome measures of this study were the median time to achieve the target hemoglobin level ({u2265}12 g/dL) and proportion of complete responders (reaching hemoglobin {u2265}12 g/dL) between Day +14 to Day +100 for patients receiving Rh Erythropoietin. Secondary end points were the proportion of patients requiring red blood cell transfusions and the total number of RBC transfusions between Day +14 and Day +100 and the area under the curve of hemoglobin between Day +14 and Day +100 after transplantation
530			_aIssued also as CD
653		4	_aAllogeneic Hematopoietic Stem Cell Transplantation (AHSCT)
653		4	_aHematopoietic Stem Cell Transplantation (HSCT)
653		4	_aNon-Myeloablative Hematopoietic Stem Cell Transplantation ( NMHCT)
700	0		_aAlaa Mohamed Elhaddad , _eSupervisor
700	0		_aLobna Mohamed Shalaby , _eSupervisor
700	0		_aMohamed Khaled Elmenabbawy , _eSupervisor
856			_uhttp://172.23.153.220/th.pdf
905			_aNazla _eRevisor
905			_aShimaa _eCataloger
942			_2ddc _cTH
999			_c76784 _d76784